The surgical robotics market in the US has finally become competitive.
In October, the FDA granted clearance to only the second robotic surgical system to date – TransEnterix‘s (NYSE:TRXC) Senhance laparoscopic platform.
The clearance was a huge milestone for the Morrisville, N.C.-based company and was quickly followed by yet another – almost exactly a month after receiving a nod from the federal watchdog, TransEnterix logged its 1st sale of the platform to the Orlando-based Florida hospital.